Assays for L-type voltage gated calcium channels

Area of Science:

• Pharmacology
• Neuroscience
• Cell Biology

Background:

• Voltage-gated calcium channels (VGCCs) are key drug targets for neurological and cardiovascular conditions.
• Current high-throughput screening methods (electrophysiology, calcium imaging) are costly and complex, often requiring cell transfection.
• There is a need for more accessible and cost-effective assays for VGCC drug discovery.

Purpose of the Study:

• To identify and characterize L-type VGCC (L-VGCC) expression in HEK-293 cells.
• To develop simplified, cost-effective assay methods for L-VGCC activity.
• To validate these assays for drug screening applications.

Main Methods:

• Detection of endogenous L-VGCC subunit proteins (Cav1.2, α2δ, β) in HEK-293 cells.
• Activation of L-VGCC using BayK8644 or KCl depolarization.
• Monitoring intracellular calcium changes with GCaMP6m live imaging.
• Utilizing an end-point assay based on calcium-dependent α-CaMKII/GluN2B interaction.

Main Results:

• Endogenous L-VGCC proteins were confirmed in HEK-293 cells, eliminating the need for transfection.
• L-VGCC activation led to measurable increases in intracellular calcium.
• Both live imaging and end-point detection methods successfully demonstrated L-VGCC activity.
• The L-VGCC antagonist nifedipine effectively blocked channel activity.

Conclusions:

• HEK-293 cells endogenously express functional L-VGCCs.
• Simple, cost-effective assays for L-VGCC activity can be established using these cells.
• These findings facilitate commercially viable drug screening for diseases involving L-VGCCs.